4 days ago
3 New Strong Buy Ratings from Top-Rated Analysts: 06/06/2025
Lucky you! Here's a complimentary look at what's trending on our most popular stock screener: 115 compelling reasons why BGC Group (BGC) is our Stock of the Week Why analysts...
This story originally appeared on WallStreetZen
Lucky you! Here's a complimentary look at what's trending on our most popular stock screener:
115 compelling reasons why BGC Group ( BGC ) is our Stock of the Week
is our Stock of the Week Why analysts are doubling down on Boston Scientific ( BSX )
Unpacking recent price target increases for Myr Group (MYRG)
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
1. Boston Scientific (NYSE: BSX)
Boston Scientific produces a very wide variety of medical devices, from run-of-the-mill pacemakers to advanced stents and brain stimulation systems. BSX is one of the most widely-covered and respected biotech names on Wall Street — and for good reason. One of the Street's top-rated analysts recently revisited their coverage of the sector — leading to a more optimistic coverage of BSX.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $105.26 — get current quote >
Max 1-year forecast: $130.00
Why we're watching:
BSX is a rare case in that it enjoys analyst coverage that is both widespread and unanimously positive — it is currently tracked by 16 analysts and has 12 Strong Buy ratings and 4 Buy ratings. See the ratings
Moreover, the average price target for Boston Scientific shares, at $117.81, implies an 11.93% upside .
. Citigroup researcher Joanne Wuensch (a top 5% rated analyst) recently doubled down on a prior Strong Buy rating, and increased her price target from $119 to $125.
Wuensch's model and price target update on Boston Scientific was delivered in a post-quarterly review of names in their Healthcare (Medical Technology) sector coverage area.
The analyst told readers that things are looking good for the sector as a whole, with fundamentals including volumes, pricing, and Capex holding.
A few days prior to Wuensch's revised coverage, Morgan Stanley's Patrick Wood (a top 15% rated analyst) also reiterated a Strong Buy rating with a $125 price target.
BSX has a Zen Rating of B, and currently ranks in the top 7% of the more than 4,600 stocks that our rating system tracks.
Boston Scientific shows remarkable performance in three categories — it ranks in the top 7% of stocks in terms of Sentiment, the top 11% when it comes to its Artificial Intelligence Component Grade rating, and the top 13% by Growth. (See all 7 Zen Component Grades here >)
2. Myr Group (NASDAQ: MYRG)
Myr Group is a specialty contractors that build and maintains electrical infrastructure across the U.S. and Canada. Its main focuses are high-voltage power lines, substations, and electrical work for large-scale industrial projects. With electrification showing no signs of stopping — coupled with constant calls for grid modernization, MYRG is set to benefit from steady demand.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $156.85 — get current quote >
Max 1-year forecast: $170.00
Why we're watching:
Myr Group stock currently has 3 Strong Buy ratings, 1 Buy rating, and 1 Hold rating. See the ratings
KeyBanc equity researcher Sangita Jain (a top 13% rated analyst) reiterated a Strong Buy rating, and increased her price target on the stock from $136 to $163.
"A strong and clean quarter highlighted by revenue growth and better-than-expected margins" was how Jain summed up the print.
The analyst told readers that KeyBanc was encouraged by the company's return to growth mode after last year's project challenges.
Looking ahead, Jain predicted that MYR Group will generate mid-to-high single-digit core revenue growth in both its segments in FY 2025.
MYRG is also the 4th highest rated stock in the Engineering & Construction industry , which has an Industry Rating of A.
, which has an Industry Rating of A. Myr Group stock has a Zen Rating of A, and ranks in the 95th percentile of equities on the whole.
A key driver behind such a high composite score is the stock's Growth Component Grade rating — in this regard, MYRG ranks in the top 2% of stocks. (See all 7 Zen Component Grades here >)
3. BGC Group (NASDAQ: BGC)
Here's our Stock of the Week, courtesy of our Zen Investor Editor-in-Chief. BGC Group clears trades across the bond, forex, and equities markets. There's a high chance that both macro factors and the regulatory shifts will benefit the stock going forward — and once you see how high it ranks in terms of several Component Grade ratings, it'll soon become apparent why Steve added BGC to his Zen Investor portfolio.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $9.32 — get current quote >
Max 1-year forecast: $15.00
Why we're watching:
BGC is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, explained why it earned a spot in his exclusive Zen Investor portfolio in a Monday article.
While Fed rate cuts have been delayed, most experts predict that 4 cuts will occur next year. Moreover, the Trump administration is committed to cutting the red tape that constrains the financial industry — and both of these factors are tailwinds for BGC Group.
The stock has gone under Wall Street's radar thus far — only 2 analysts cover it, but both issue Strong Buy ratings, with an average price target of $14.50 — which implies a 56.08% upside. See the ratings
With the stock's impressive beat and raise earnings reports, Steve would not be surprised if BGC shares rocketed to levels near the $20 mark.
At present, the stock has a Zen Rating of A, and ranks in the top 4% of the equities we track.
For a better idea as to why our system rates it so highly, we have to take a look at its Component Grade ratings. BGC ranks in the top 12% in terms of Growth and Financials.
However, the stock also ranks quite highly in terms of Artificial Intelligence and Value — in the top 14% and 16%, respectively. ( See all 7 Zen Component Grades here > )
What to Do Next?
